Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR.

Sartore-Bianchi A, Siena S, Tonini G, Bardelli A, Santini D.

Cancer Treat Rev. 2016 Dec;51:54-62. doi: 10.1016/j.ctrv.2016.10.006. Epub 2016 Oct 29. Review.

PMID:
27865140
2.

Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.

Napolitano S, Martini G, Rinaldi B, Martinelli E, Donniacuo M, Berrino L, Vitagliano D, Morgillo F, Barra G, De Palma R, Merolla F, Ciardiello F, Troiani T.

Clin Cancer Res. 2015 Jul 1;21(13):2975-83. doi: 10.1158/1078-0432.CCR-15-0020. Epub 2015 Apr 2.

3.

Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.

Lee JJ, Chu E.

Clin Colorectal Cancer. 2014 Sep;13(3):135-44. doi: 10.1016/j.clcc.2014.02.001. Epub 2014 Feb 27. Review.

4.

Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer.

Abrams TA, Meyer G, Schrag D, Meyerhardt JA, Moloney J, Fuchs CS.

J Natl Cancer Inst. 2014 Feb;106(2):djt371. doi: 10.1093/jnci/djt371.

PMID:
24511107
5.

Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.

Al-Marrawi MY, Saroya BS, Brennan MC, Yang Z, Dykes TM, El-Deiry WS.

Cancer Biol Ther. 2013 Aug;14(8):703-10. doi: 10.4161/cbt.25191. Epub 2013 Jun 13.

6.

The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.

García-Alfonso P, Grande E, Polo E, Afonso R, Reina JJ, Jorge M, Campos JM, Martínez V, Angeles C, Montagut C.

Angiogenesis. 2014 Oct;17(4):805-21. doi: 10.1007/s10456-014-9433-6. Epub 2014 May 3. Review.

PMID:
24793846
7.

Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.

Schmieder R, Hoffmann J, Becker M, Bhargava A, Müller T, Kahmann N, Ellinghaus P, Adams R, Rosenthal A, Thierauch KH, Scholz A, Wilhelm SM, Zopf D.

Int J Cancer. 2014 Sep 15;135(6):1487-96. doi: 10.1002/ijc.28669. Epub 2014 Apr 17.

8.

Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer.

Jeong WJ, Cha PH, Choi KY.

World J Gastroenterol. 2014 Aug 7;20(29):9862-71. doi: 10.3748/wjg.v20.i29.9862. Review.

9.

Selection of biologics for patients with metastatic colorectal cancer: the role of predictive markers.

Kasi PM, Hubbard JM, Grothey A.

Expert Rev Gastroenterol Hepatol. 2015 Mar;9(3):273-6. doi: 10.1586/17474124.2015.1001743. Epub 2015 Jan 12. Review.

PMID:
25579664
10.

A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer.

Do K, Cao L, Kang Z, Turkbey B, Lindenberg ML, Larkins E, Holkova B, Steinberg SM, Raffeld M, Peer CJ, Figg WD, Eugeni M, Jacobs P, Choyke P, Wright JJ, Doroshow JH, Kummar S.

Clin Colorectal Cancer. 2015 Sep;14(3):154-61. doi: 10.1016/j.clcc.2015.02.007. Epub 2015 Mar 7.

PMID:
25861837
11.

Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer.

Lee MS, Kopetz S.

Clin Colorectal Cancer. 2015 Dec;14(4):203-18. doi: 10.1016/j.clcc.2015.05.006. Epub 2015 May 29. Review.

PMID:
26077270
12.

Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.

Tol J, Punt CJ.

Clin Ther. 2010 Mar;32(3):437-53. doi: 10.1016/j.clinthera.2010.03.012. Review.

PMID:
20399983
13.

Treatment decisions in metastatic colorectal cancer - Beyond first and second line combination therapies.

Vogel A, Hofheinz RD, Kubicka S, Arnold D.

Cancer Treat Rev. 2017 Sep;59:54-60. doi: 10.1016/j.ctrv.2017.04.007. Epub 2017 May 4. Review.

14.

Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.

László L.

Magy Onkol. 2010 Dec;54(4):383-94. doi: 10.1556/MOnkol.54.2010.4.13.

15.

Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies.

Zhang W, Gordon M, Lenz HJ.

Ann Med. 2006;38(8):545-51. Review.

PMID:
17438669
16.

[Targeted therapies for metastatic colorectal cancer].

Kito Y, Yamazaki K.

Nihon Rinsho. 2015 Aug;73(8):1384-90. Review. Japanese.

PMID:
26281694
17.

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.

Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, Lowe C, Seligmann JF, Wadsley J, Maisey N, Chau I, Hill M, Dawson L, Falk S, O'Callaghan A, Benstead K, Chambers P, Oliver A, Marshall H, Napp V, Quirke P.

Lancet Oncol. 2013 Jul;14(8):749-59. doi: 10.1016/S1470-2045(13)70163-3. Epub 2013 May 29.

18.

Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution.

Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A.

Cancer Discov. 2014 Nov;4(11):1269-80. doi: 10.1158/2159-8290.CD-14-0462. Epub 2014 Oct 7. Review.

19.

Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.

Ruzzo A, Graziano F, Canestrari E, Magnani M.

Curr Cancer Drug Targets. 2010 Feb;10(1):68-79. Review.

PMID:
20088793
20.

Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2013 Jul;15(7):517-27. doi: 10.1038/gim.2012.184. Epub 2013 Feb 21.

PMID:
23429431

Supplemental Content

Support Center